

Research Note: Likelihood of Hemangiosarcoma in Dogs with Hemoabdomen

Nontraumatic hemoabdomen is costly to evaluate and treat. Considering the likelihood of hemangiosarcoma, many dogs with hemoabdomen are euthanized without undergoing surgery. The ability to evaluate and determine patient risk for developing hemangiosarcoma may help facilitate recommendations for clinicians and decision-making for owners. A retrospective study of 406 dogs from 5 veterinary medical centers helped develop a prediction model known as the Hemangiosarcoma Likelihood Prediction (HeLP). Using data from 219 dogs, an algorithm was developed to calculate a score (0-100) based on 4 variables (ie, body weight, total plasma protein, platelet count, thoracic radiograph findings). The patients were divided into the following risk groups based on their HeLP score: low (0-40), medium (41-55), and high (>55); incidence of a hemangiosarcoma diagnosis on histopathology according to risk group was 36%, 76%, and 96%, respectively. HeLP scores were then validated in a separate population of 187 dogs, demonstrating good discrimination. The HeLP score can be further refined with larger study groups.

Source

Schick AR, Hayes GM, Singh A, et al. Development and validation of a hemangiosarcoma likelihood prediction model in dogs presenting with spontaneous hemoabdomen: the HeLP score. *J Vet Emerg Crit Care (San Antonio)*. 2019;29(3):239-245.

entyce®
(capromorelin oral solution)

30 mg/mL

BRIEF SUMMARY: Before using this product, please consult the full product insert for more information.

For oral use in dogs only

Appetite Stimulant

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: ENTYCE® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion.

Indication: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

Contraindications: ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.

Warnings: Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. **For use in dogs only**

Precautions: Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Adverse Reactions: Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTYCE (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting.

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-640-5500.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

NADA 141-457, Approved by FDA

US Patent: 6,673,929

US Patent: 9,700,591

Made in Canada

ARATANA
THERAPEUTICS®

Manufactured for:
Aratana Therapeutics, Inc.
Leawood, KS 66211

ENTYCE is a trademark of Aratana Therapeutics, Inc.

© Aratana Therapeutics, Inc.

AT2-051-1

February 2018